ARTHEx nabs Series B for clinical trial of ASO in myotonic dystrophy as Vertex’s deals heat up the space
ARTHEx Biotech has raised €42 million (about $46 million) in Series B funds to bankroll an early-stage study of a drug candidate in myotonic dystrophy type 1, or DM1.
The Valencia, Spain-based startup will enter the clinic in the second half of this year with an IV-delivered drug candidate for people with the rare neuromuscular disorder.
Muscle weakness is a common result of DM1 and impacts about 40,000 people in the US and 70,000 in Europe. Those are the two geographies where ARTHEx will investigate ATX-01 in Phase I/IIa, said chair and new CEO Frédéric Legros in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
